MZL
MCID: MRG003
MIFTS: 52

Marginal Zone B-Cell Lymphoma (MZL) malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

Aliases & Descriptions for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 38 12 14 69
Marginal Zone Lymphoma 12 50
Mucosa-Associated Lymphoid Tissue Lymphoma 69
Mzl 50

Classifications:



External Ids:

Disease Ontology 12 DOID:0050748

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to primary cutaneous marginal zone b-cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is MALT1 (MALT1 Paracaspase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, lung and thyroid, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and endocrine/exocrine gland

Wikipedia : 71 Marginal zone lymphomas are a group of slow-growing non-Hodgkin B-cell lymphomas, which account for... more...

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Related Disease Score Top Affiliating Genes
1 primary cutaneous marginal zone b-cell lymphoma 12.5
2 nodal marginal zone b-cell lymphoma 12.5
3 lymphoma, malt, somatic 11.9
4 splenic marginal zone lymphoma 11.3
5 lymphoma 11.2
6 b-cell lymphomas 11.2
7 b-cell lymphoma of mucosa-associated lymphoid tissue 10.8
8 hepatitis 10.4
9 diffuse large b-cell lymphoma 10.3
10 amyloidosis 10.3
11 histiocytosis 10.3
12 thyroiditis 10.3
13 mantle cell lymphoma 10.2
14 arthritis 10.2
15 teratocarcinoma 10.2 BCL2 CD5
16 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 10.2 BCL2 CD5
17 symptomatic form of hemophilia a in female carriers 10.2 IRF4 MYD88
18 rubella panencephalitis 10.2 BCL2 BCL6 MALT1
19 prader-willi syndrome due to paternal deletion of 15q11q13 type 1 10.2 BCL10 IRF4 MALT1
20 rheumatoid arthritis 10.2
21 hepatitis c 10.2
22 macroglobulinemia 10.2
23 ichthyosis, congenital, autosomal recessive 10 10.2 BCL10 BCL2 BCL6
24 chondrodysplasia punctata, tibia-metacarpal type 10.2 CD40LG CD5
25 penile disease 10.2 BCL6 CD5 IRF4
26 mu chain disease 10.1 CD40LG MYD88
27 male infertility 10.1 BCL2 CCND1
28 primary tubular proximal acidosis 10.1 BCL2 MYD88
29 plasmacytoma 10.1
30 leukemia 10.1
31 hepatitis c virus 10.1
32 polycystic bone disease 10.1 CCND1 IRF4
33 pyloric antrum cancer 10.1 BCL10 BCL2 BCL6 MALT1
34 brca1 and brca2 hereditary breast and ovarian cancer 10.1 BCL10 BCL6 BIRC3 MALT1
35 carnitine-acylcarnitine translocase deficiency 10.1 BCL2 BCL6 IRF4
36 acute allergic sanguinous otitis media 10.1 BCL2 CCND1
37 ethmoid sinus inverted papilloma 10.1 BCL6 MME
38 colonic benign neoplasm 10.1 CD40LG MYD88
39 arteriosclerosis 10.1 CD40LG CD5 MYD88
40 uterine ligament endometrioid adenocarcinoma 10.1 CCND1 CD5
41 hypopituitarism 10.0 CD40LG TNFAIP3
42 adenocarcinoma 10.0
43 meningitis 10.0
44 gastric cancer 10.0
45 dacryoadenitis 10.0
46 systemic lupus erythematosus 10.0
47 chlamydia 10.0
48 composite lymphoma 10.0
49 peripheral t-cell lymphoma 10.0
50 lupus erythematosus 10.0

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

GenomeRNAi Phenotypes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 CD40LG MALT1 MYD88 TNFAIP3 BCL10 BCL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 CD40LG MALT1 MYD88 TNFAIP3 BCL10 BCL2

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.7 BCL10 BCL2 BCL6 CCND1 CD40LG MYD88
2 hematopoietic system MP:0005397 9.7 BCL10 BCL2 BCL6 BIRC3 CCND1 CD40LG
3 immune system MP:0005387 9.4 IRF4 MALT1 MME MYD88 TNFAIP3 BCL10

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 482)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
3
Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
4
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
5
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
6
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
9 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
11 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
21
Proton pump inhibitors Phase 4,Phase 3,Phase 2
22 Antacids Phase 4,Phase 2
23 Anti-Ulcer Agents Phase 4,Phase 2
24 Antimalarials Phase 4,Phase 2,Phase 1
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
27
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
28
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
29
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
30
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
31
Idarubicin Approved Phase 3 58957-92-9 42890
32
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
33
Vidarabine Approved Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
34
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
35
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
36
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
37
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
38
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
39
Ofloxacin Approved Phase 3 82419-36-1 4583
40
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
41
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
42
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
44
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
45
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
46
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
47
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
48
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
50
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 687)
id Name Status NCT ID Phase
1 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
3 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Not yet recruiting NCT02959255 Phase 4
4 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Not yet recruiting NCT02553083 Phase 4
5 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
9 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3
10 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3
11 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
13 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
16 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
17 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3
18 A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
19 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3
20 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
21 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3
22 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3
23 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3
26 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3
27 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3
28 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
29 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
30 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
31 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
32 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
33 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
34 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
35 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
36 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
37 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
38 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
39 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
40 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
42 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3
43 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
44 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
45 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
46 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
47 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
48 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
49 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. Recruiting NCT01996865 Phase 3
50 Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma Recruiting NCT01701232 Phase 3

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

39
B Cells, Lung, Thyroid, Skin, Salivary Gland, Breast, Thymus

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 395)
id Title Authors Year
1
Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. ( 27460179 )
2016
2
Paediatric primary cutaneous marginal zone B-cell lymphoma: Does it differ from the adult counterpart? ( 27501236 )
2016
3
Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter? ( 27548082 )
2016
4
Primary Cutaneous Marginal Zone B-Cell Lymphoma Presenting as a Small Mass on Temple Area. ( 27152562 )
2016
5
Lacrimal gland extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue-type associated with massive amyloid deposition. ( 27010357 )
2016
6
Primary Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lacrimal Sac Found with Epiphora: A Case Report. ( 27790131 )
2016
7
Extranodal pulmonary marginal zone B-cell lymphoma. ( 27330951 )
2016
8
Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa. ( 27218791 )
2016
9
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. ( 27443419 )
2016
10
Misdiagnosis of primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, a case report. ( 26956381 )
2016
11
Epidermotropic skin involvement of splenic marginal zone B-cell lymphoma: a diagnostic challenge. ( 28008643 )
2016
12
Intracranial marginal zone B-cell lymphoma mimicking meningioma: case report. ( 27155383 )
2016
13
MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. ( 25723115 )
2015
14
Marginal zone B-cell lymphoma of the pulmonary mucosa-associated lymphoid tissue: A case report. ( 26622741 )
2015
15
Bilateral Bronchiectasis as a Presentation Form of Pulmonary Marginal Zone B-Cell Lymphoma of Bronchus Associated Lymphoid Tissue. ( 26839723 )
2015
16
Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells. ( 26111022 )
2015
17
Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis. ( 25988528 )
2015
18
A case of contiguous primary hepatic marginal zone B-cell lymphoma and hemangioma ultimately diagnosed using contrast-enhanced ultrasonography. ( 25848352 )
2015
19
A 44-year old male with right-sided facial numbness. Dura-associated extranodal marginal zone B cell lymphoma (MALT lymphoma). ( 25521183 )
2015
20
Primary extranodal marginal zone B-cell lymphoma with diffuse uveal involvement and focal infiltration of the trabecular meshwork: a case report and review of literature. ( 25947067 )
2015
21
Primary Cutaneous Marginal Zone B Cell Lymphoma of the Eyelid Skin: Diagnostic Clues and Distinction from Other Ocular Adnexal Disease. ( 26545575 )
2015
22
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Tissue Type involving the Dura. ( 26194368 )
2015
23
A case of marginal zone B cell lymphoma mimicking IgG4-related dacryoadenitis and sialoadenitis. ( 25889621 )
2015
24
77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). ( 25521182 )
2015
25
Primary thymic extranodal marginal zone B cell lymphoma as an incidental finding in a Caucasian woman. ( 26338245 )
2015
26
A rare case of splenic marginal zone B-cell lymphoma mimicking relapsing polychondritis of the ear. ( 25544924 )
2014
27
Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 23925930 )
2014
28
Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. ( 25338969 )
2014
29
Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. ( 25407794 )
2014
30
Extranodal marginal zone B cell lymphoma of the orbit in a patient with sarcoidosis: a case report. ( 25363228 )
2014
31
Nodal involvement by marginal zone B-cell lymphoma harboring t(14;22)(q32;q11) involving immunoglobulin heavy chain and light chain lambda as the sole karyotypically recognizable abnormality in a patient with systemic lupus erythematosus. ( 25197401 )
2014
32
PD-1, S-100, and CD1a Expression in Pseudolymphomatous Folliculitis, Primary Cutaneous Marginal Zone B-cell Lymphoma (MALT lymphoma), and Cutaneous Lymphoid Hyperplasia. ( 25384543 )
2014
33
Primary thyroid marginal zone B-cell lymphoma in a patient with psoriatic arthritis treated with etanercept. ( 25219743 )
2014
34
Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C. ( 25024777 )
2014
35
Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas. ( 25320370 )
2014
36
Cutaneous Marginal Zone B-cell Lymphoma Evolving into Anetoderma: A Role of Matrix Metalloproteinases? ( 25350822 )
2014
37
Patients with Helicobacter pylori negative gastric marginal zone b-cell lymphoma (MZBCL) of MALT have a good prognosis. ( 25474277 )
2014
38
High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with SjAPgren's syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. ( 24447326 )
2014
39
Acquired angioedema with C1 inhibitor deficiency secondary to splenic marginal zone B-cell lymphoma. ( 24970460 )
2014
40
Crystal storing histiocytosis associated with marginal zone B-cell lymphoma: A rare initial clinical presentation diagnosed by fine-needle aspiration. ( 25071859 )
2014
41
Nodal marginal zone B-cell lymphoma showing prominent plasma cell differentiation in the pleural effusion: A case report. ( 22833332 )
2014
42
Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. ( 24411627 )
2014
43
Concurrent Lung Squamous Cell Carcinoma and Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type. ( 24419198 )
2014
44
Extranodal marginal zone B-cell lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma) in ulcerative colitis. ( 25253369 )
2014
45
Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. ( 24769492 )
2014
46
IgG4-related dacryoadenitis evolving into an extra-nodal, marginal zone B-cell lymphoma (EMZL): a tale of two lacrimal glands. ( 24977741 )
2014
47
Crystal-storing histiocytosis complicating marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. ( 25216699 )
2014
48
Treatment outcome of gastric extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in the Hong Kong Chinese population: a single centre experience. ( 23730516 )
2013
49
Is there a role for capsule endoscopy in the staging work-up of patients with gastric marginal zone B-cell lymphoma of MALT? ( 23955137 )
2013
50
Localized conjunctival extra-nodal marginal zone B cell lymphoma with presumed Paraproteinic Crystalline Keratopathy. ( 23361873 )
2013

Variations for Marginal Zone B-Cell Lymphoma

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

Pathways related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 BCL10 BCL2 BCL6 BIRC3 C1S CCND1
2
Show member pathways
13.18 BCL2 BCL6 BIRC3 CCND1 CD40LG IRF4
3
Show member pathways
12.77 BCL10 BCL2 BIRC3 MALT1 MYD88 TNFAIP3
4
Show member pathways
12.49 BCL10 CD40LG MALT1 MYD88 TNFAIP3
5
Show member pathways
12.46 BCL2 BIRC3 CD40LG MYD88 TNFAIP3
6
Show member pathways
12.31 BCL10 CD40LG IRF4 MALT1
7
Show member pathways
12.24 BCL10 BCL6 IRF4 MALT1
8
Show member pathways
12.08 BCL2 BIRC3 CD40LG MYD88
9 12.05 BCL10 BCL2 MALT1 MYD88
10 12 BCL10 BCL6 CD40LG IRF4 MALT1 MYD88
11 11.9 BCL10 BCL2 BIRC3 CD40LG MALT1 TNFAIP3
12 11.85 BCL2 BCL6 CCND1
13
Show member pathways
11.85 BCL2 BIRC3 TNFAIP3
14 11.76 BCL2 BCL6 CCND1 IRF4
15 11.71 BCL2 BIRC3 CCND1
16 11.66 BCL2 BIRC3 CCND1
17
Show member pathways
11.62 BCL2 BIRC3 CD40LG
18 11.61 MALT1 MYD88 TNFAIP3
19 11.53 BCL6 CD40LG IRF4
20
Show member pathways
11.52 BIRC3 CCND1 CD40LG
21 11.28 BCL6 CD40LG CD5 MME
22 11.15 BCL10 BCL2 BIRC3 CD40LG MALT1 MYD88
23 11.09 BIRC3 CD40LG TNFAIP3
24 10.91 BCL10 MALT1 TNFAIP3

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.35 BCL10 BCL2 BIRC3 MALT1 MYD88
2 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.93 BCL10 BCL2 BIRC3 MYD88 TNFAIP3
2 immune system process GO:0002376 9.88 BCL10 BCL6 C1S MYD88
3 inflammatory response GO:0006954 9.86 BCL6 CD40LG MYD88 TNFAIP3
4 negative regulation of apoptotic process GO:0043066 9.8 BCL2 BCL6 BIRC3 CD40LG MALT1 MYD88
5 protein oligomerization GO:0051259 9.69 BCL10 MALT1 TNFAIP3
6 B cell differentiation GO:0030183 9.67 BCL2 BCL6 CD40LG
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 BCL10 CD40LG MALT1 MYD88
8 regulation of apoptotic process GO:0042981 9.65 BCL10 BCL2 BCL6 BIRC3 MALT1
9 positive regulation of protein ubiquitination GO:0031398 9.63 BCL10 BIRC3 MALT1
10 positive regulation of T cell activation GO:0050870 9.57 BCL10 MALT1
11 response to iron ion GO:0010039 9.55 BCL2 CCND1
12 immunoglobulin mediated immune response GO:0016064 9.52 BCL10 MYD88
13 response to fungus GO:0009620 9.48 BCL10 MALT1
14 regulation of inflammatory response GO:0050727 9.46 BCL6 BIRC3 MYD88 TNFAIP3
15 regulation of T cell receptor signaling pathway GO:0050856 9.43 BCL10 MALT1
16 regulation of germinal center formation GO:0002634 9.4 BCL6 TNFAIP3
17 response to molecule of bacterial origin GO:0002237 9.13 BCL10 MALT1 TNFAIP3
18 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.02 BCL10 BIRC3 MALT1 MYD88 SLC35B2

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 BCL10 BCL2 BCL6 C1S MYD88 TNFAIP3
2 transcription factor binding GO:0008134 9.62 BCL10 BCL2 CCND1 IRF4
3 kinase activator activity GO:0019209 9.26 BCL10 MALT1
4 protease binding GO:0002020 9.26 BCL10 BCL2 MALT1 TNFAIP3
5 protein self-association GO:0043621 8.92 BCL10 MALT1 MYD88 TNFAIP3
6 protein binding GO:0005515 10.18 BCL10 BCL2 BCL6 BIRC3 C1S CCND1

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....